KPV: the anti-inflammatory tripeptide with no human data and a favourable FDA vote

KPV is the C-terminal tripeptide of α-melanocyte-stimulating hormone — the fragment at positions 11 to 13, which is why the literature often writes it as α-MSH(11-13) ^[1]. Molecular formula C₁₆H₃₀N₄O₄, molecular weight 342.43 daltons, PubChem CID 125672 ^[2]. For scale: BPC-157 is fifteen amino acids, MOTS-c is sixteen. KPV is about as small as a peptide gets before it stops being called one.

α-MSH itself is a thirteen-residue hormone cleaved from pro-opiomelanocortin, best known for driving pigmentation and appetite signalling. It is also strongly anti-inflammatory. The interest in KPV comes from a specific finding: the fragment keeps most of the parent hormone's anti-inflammatory activity while losing the pigmentary effect ^[3].

There is a detail here that matters more than it first appears. KPV does not work the way α-MSH works. A 2010 review by Brzoska and colleagues states it plainly: the tripeptide "lacks the entire sequence motif required for binding to any of the known MC-Rs" — the melanocortin receptors through which α-MSH acts — and yet "retains almost all of the anti-inflammatory capacity of the full hormone" ^[4]. The same review says the exact signalling mechanism used by KPV "currently is unknown."

Keep that in mind when reading marketing copy. Some vendor pages claim KPV binds MC1R or MC3R. The peer-reviewed literature says it cannot.

If KPV doesn't use a receptor, how does it act? The answer turns out to be a transporter, and it is the most solidly established fact about this peptide.

PepT1 is an oligopeptide transporter that normally moves di- and tripeptides across the small-intestinal wall. It is barely present in a healthy colon — but it is switched on in colonic epithelium during intestinal inflammation. In 2008 Dalmasso and colleagues at Emory showed that KPV is a PepT1 substrate: they measured uptake kinetics with tritium-labelled KPV, competed it against a known PepT1 substrate, and demonstrated that the peptide's anti-inflammatory effect depends on PepT1 being expressed in the cells receiving it ^[5].

Once inside, KPV suppresses NF-κB and MAP-kinase signalling and reduces pro-inflammatory cytokine secretion — at nanomolar concentrations, per the same paper ^[5]. A later Chinese group used KPV as the targeting moiety of a fluorescent probe and confirmed the transport route in a human Caco-2 colitis model, with the peptide accumulating in cytoplasm and nucleus ^[6].

The architecture of that mechanism has an implication most consumer coverage misses. PepT1 is upregulated by inflammation, in the gut wall. So the best-evidenced mode of action for KPV is local, at inflamed intestinal tissue, through a transporter that only shows up when the tissue is already inflamed. That is a narrow and specific story. It is not a story about a peptide circulating in blood and reducing inflammation everywhere.

There are two foundational rodent studies and both are real.

Dalmasso 2008, in Gastroenterology, gave KPV to mice in their drinking water and induced colitis two ways, with dextran sodium sulphate and with TNBS. Oral KPV reduced the incidence of colitis in both models, measured histologically and by pro-inflammatory cytokine messenger RNA ^[5].

Kannengiesser 2008, in Inflammatory Bowel Diseases, ran two different colitis models — DSS and CD45RB^hi transfer colitis — and tracked weight loss, colon histology and myeloperoxidase activity. KPV-treated mice recovered earlier and regained significantly more weight, with significantly reduced inflammatory infiltrate and MPO. The striking result was in a third arm: mice engineered with a non-functional melanocortin-1 receptor, given DSS. KPV treatment "rescued all animals in the treatment group from death" ^[1]. That is both a large effect and independent confirmation that the peptide is not working through MC1R.

Since then the work has moved almost entirely into drug delivery rather than new biology. A 2017 Molecular Therapy paper built hyaluronic-acid-functionalised nanoparticles, about 272 nm across, to carry KPV orally to colonic epithelium and macrophages ^[7]. A 2024 Frontiers in Pharmacology group co-assembled KPV with the immunosuppressant FK506 into a PepT1-targeted nanodrug and tested it in acute and chronic DSS colitis; the combination outperformed either agent alone on weight recovery, disease activity index and colon length ^[8]. A 2016 study in Cellular and Molecular Gastroenterology and Hepatology extended the model into colitis-associated cancer ^[9].

Outside the gut, the evidence thins fast. The one recent skin study is in vitro: human HaCaT keratinocytes exposed to particulate matter, where 50 µg/mL KPV restored viability, cut interleukin-1β secretion, suppressed reactive oxygen species and NF-κB, and reduced cleaved caspase-3 ^[10]. Cells in a dish, not skin on a person. A 2000 paper found that α-MSH and KPV inhibited Staphylococcus aureus and Candida albicans in vitro ^[11], and that antimicrobial finding does not appear to have been replicated since.

The widely repeated claim that topical KPV speeds wound closure by twenty or thirty per cent traces, as far as we can establish, to vendor pages that cite no study at all. We could not find a primary source for it.

Here is the number that should govern how anyone thinks about buying KPV.

In 2017 a group at Auburn tested how well KPV crosses human skin, using dermatomed human tissue. By simple passive diffusion — a cream on skin, in effect — KPV permeation was below the limit of detection, that limit being 0.01 µg/mL. Not low. Undetectable. Microneedles got it to 4.4 µg/cm²/h; iontophoresis multiplied that eightfold; the two combined, thirty-fivefold ^[12].

So a plain topical KPV preparation, absent microneedling or an electric current, has no demonstrated ability to get the peptide into skin at all.

The oral picture is subtler but points the same way. Peptide drugs generally have oral bioavailability below two per cent, destroyed by gastric acid and intestinal proteases before absorption. KPV's animal efficacy came from drinking water in mice and is explained by local PepT1 uptake at the inflamed gut wall — not by systemic absorption. And every advance since 2017 has been an encapsulation strategy: nanoparticles, hyaluronic-acid coatings, PepT1-targeted carriers. Researchers do not spend a decade engineering delivery vehicles for a molecule that already gets where it needs to go.

There is no published pharmacokinetic study of KPV in any species, by any route. No plasma concentration, no half-life, no bioavailability figure. That is a striking gap for a compound being sold in capsules and nasal sprays.

There is none.

No randomised trial. No open-label series. No case reports. No pharmacokinetic or tolerability study. ClinicalTrials.gov returns zero registered studies for KPV or lysine-proline-valine, unfiltered by status, which means not even a terminated or recruiting one ^[16].

The human tissue that appears in the literature is ex vivo skin in the permeation study and immortalised cell lines — HaCaT keratinocytes, Caco-2 and HT29 intestinal cells, Jurkat T cells. Those are legitimate experimental systems and they are not people.

This distinction gets blurred routinely. Vendor and clinic pages describe dosing "based on individual patient presentation", practitioner-reported outcomes, and oral versus injectable protocols. That language describes a market, not an evidence base. Several of those same pages concede the point in their own fine print: one states flatly that KPV has zero human clinical trials and that all proposed benefits are extrapolated from cell culture and mouse studies.

Every safety observation available is preclinical and incidental — cytocompatibility notes inside efficacy or imaging papers. The nanoparticle formulations were described as non-toxic to intestinal cells ^[7]; the fluorescent probe showed negligible cytotoxicity ^[6]; the KPV-plus-FK506 nanodrug produced no organ histology toxicity in mice after seven days, though that assessment was of the nanoparticle given intravenously, not of KPV ^[8].

There is no dedicated toxicology study of KPV itself. No human safety data of any kind. No long-term data in any species.

The class-level risks that apply to any injectable peptide bought outside a regulated supply chain apply here in full: unverified identity and purity, endotoxin contamination, non-sterile handling. A 2026 review in the Journal of Sports Medicine and Physical Fitness names KPV among fragments marketed for recovery, notes that clinical evidence for peptide use in sport is limited, and flags that the supply chain is largely unregulated with products often mislabelled or contaminated ^[13]. The specific adverse effects that review discusses are not attributed to KPV, and we are not attributing them to it here.

The honest formulation is uncomfortable but simple: KPV has not been shown to be dangerous, and it has not been studied in humans well enough for anyone to say it is safe.

KPV went before the FDA's Pharmacy Compounding Advisory Committee on July 23, 2026, under docket FDA-2025-N-6895. The use the agency evaluated was wound healing and inflammatory conditions.

FDA's own reviewers proposed not to add it to the 503A bulks list. The committee disagreed, voting 8 in favour, 6 against, with 1 abstention — separately for the free base and the acetate salt, landing the same way both times ^[14]. KPV was one of six peptides the committee recommended that day against the agency's stated position; only emideltide was rejected. Our report on the meeting has the full record with timestamps into FDA's own webcast.

What that does and does not mean needs stating precisely, because it is being widely misreported. A committee recommendation is advisory and non-binding. FDA has issued no final determination. KPV is not on the 503A positive list, has no USP monograph, and is not a component of any approved drug — which are the three routes by which a bulk substance becomes legally compoundable. Placement on the list happens through rulemaking: a proposed rule in the Federal Register, a comment period, a final rule. None of that has begun, and there is no published timeline.

Removal from a prohibition is not the same as permission. As one law-firm analysis of the twelve peptides FDA pulled out of Category 2 in April 2026 put it, those substances "are no longer designated as posing a 'significant safety risk,' but they have not been affirmatively authorized for compounding under Section 503A or FDA guidance" ^[15].

So the status today: not prohibited, not authorised. A pharmacy needs the permission, not the absence of a ban.

Meanwhile KPV is sold widely under "research use only" labelling. FDA's position on that label is now well documented across a run of warning letters to peptide sellers — the disclaimer does not survive marketing copy that shows human intent. See our coverage of those letters.

KPV is the rare wellness peptide where the mechanism is genuinely interesting and specifically characterised: a receptor-independent anti-inflammatory that enters cells through a transporter switched on by inflammation itself. The colitis work in mice is reproducible across two labs and four models, and the effect in the MC1R-deficient survival experiment was large.

None of that has been tested in a human being. The delivery data suggest that the forms most commonly sold — a plain topical, an unencapsulated oral — are the two least likely to deliver the peptide anywhere useful. And the favourable FDA committee vote, which is being marketed as a green light, changed nothing about what a pharmacy may legally prepare.

If this is a promising drug candidate, the next step is a Phase 1 trial, and nobody has run one. What would move this page meaningfully: a registered human study of any size, a pharmacokinetic profile by any route, or an actual FDA determination following the July vote. Until then the file reads the way it reads.